Nautilus Biotechnology, Inc.
NAUT
Last
$2.25
Day
+23.6%
1y
+102.2%
5y
-68.8%
52w
-57.8%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-10-2616d
EMA 21
1.43
EMA 50
1.33
EMA 200
1.72
20d high
-26.5%
5y high
-71.2%
5y range
21th
Positions held
Your positionsNAUT isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
55
Hold
swing
Signal
Strong Buy
Target
$2.34
Stop
$1.39
Stop distance
38.2%
Target vs last
+4.0%
Fundamentals
| Market cap | $293.95M | Enterprise value | $175.39M | Trailing P/E | — | Forward P/E | -3.12 |
| PEG | — | Price / book | 2.24 | Beta | 0.73 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 92.1% | Operating margin | -83.0% |
| Profit margin | 0.0% | ROE | -36.2% | ROA | -20.8% | Debt / equity | 0.21 |
| Current ratio | 10.14 | Free cash flow | -$29.42M | Analyst recommendation | strong_buy | Mean target | $3.83 |
| 52w high | $4.31 | 52w low | $0.82 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -157630.0% | — | — | — | — | — |
| Net income | -$14.5M | -$14.7M | -$13.8M | -$13.6M | -$15.0M | — |
| Gross margin | -50.0% | — | — | — | — | — |
| Gross profit | -$0.0M | — | — | — | $0.0M | — |
| Operating income | -$15.8M | -$16.1M | -$15.4M | -$15.5M | -$17.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$59.0M | -$70.8M | -$63.7M | -$57.9M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$66.8M | -$81.5M | -$76.2M | -$63.6M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-11 · Nautilus Biotechnology Files $300 Million Shelf Registration
2026-07-28 · Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and ...
2026-07-28 · Nautilus Biotechnology Q2 Earnings Call Highlights
2026-07-28 · Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patternsNAUT · daily+82.1% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin